Success Metrics

Clinical Success Rate
100.0%

Based on 10 completed trials

Completion Rate
100%(10/10)
Active Trials
0(0%)
Results Posted
20%(2 trials)

Phase Distribution

Ph not_applicable
6
46%
Ph phase_3
1
8%
Ph phase_1
2
15%
Ph phase_2
4
31%

Phase Distribution

2

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
2(15.4%)
Phase 2Efficacy & side effects
4(30.8%)
Phase 3Large-scale testing
1(7.7%)
N/ANon-phased studies
6(46.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

10 of 10 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

13

all time

Status Distribution
Completed(10)
Other(3)

Detailed Status

Completed10
unknown3

Development Timeline

Analytics

Development Status

Total Trials
13
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (15.4%)
Phase 24 (30.8%)
Phase 31 (7.7%)
N/A6 (46.2%)

Trials by Status

completed1077%
unknown323%

Recent Activity

0 active trials
Showing 5 of 13
completedphase_2

Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal Meningitis

NCT06414512
unknownnot_applicable

Clinical Study of ABCD in the Treatment of Cryptococcal Meningitis

NCT05471063
completednot_applicable

A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis

NCT00000639
completedphase_2

Dexamethasone in Cryptococcal Meningitis

NCT00000776
completedphase_1

Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas

NCT02015819
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT06414512Phase 2

Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal Meningitis

Completed
NCT05471063Not Applicable

Clinical Study of ABCD in the Treatment of Cryptococcal Meningitis

Unknown
NCT00000639Not Applicable

A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis

Completed
NCT00000776Phase 2

Dexamethasone in Cryptococcal Meningitis

Completed
NCT02015819Phase 1

Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas

Completed
NCT04140461Phase 3

AmB Dose for Cryptococcal Meningitis

Unknown
NCT01172964Phase 1

A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas

Completed
NCT01715922Phase 2

Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Sub-saharan Africa

Unknown
NCT00000708Not Applicable

Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis

Completed
NCT00012467Phase 2

Safety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Cryptococcal Meningitis

Completed
NCT00002075Not Applicable

Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis

Completed
NCT00002113Not Applicable

A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis.

Completed
NCT00002305Not Applicable

A Comparison of Fluconazole and Amphotericin B in the Treatment of Cryptococcal Meningitis

Completed

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13